Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John-Philip Lawo

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Journal of Clinical Immunology|February 25, 2016
Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary ImmunodeficiencyMikhail A Rojavin, Alphonse Hubsch, John-Philip Lawo
Journal of Biopharmaceutical Statistics|May 25, 2010
Establishing bioequivalence in complete and incomplete data designs using AUCsThomas Jaki, Martin J Wolfsegger, John-Philip Lawo
Journal of Pharmaceutical and Biomedical Analysis|September 10, 2013
A comparison of methods for classifying samples as truly specific with confirmatory immunoassaysThomas Jaki, John-Philip Lawo, Martin J Wolfsegger, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|October 11, 2020
Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) studyVera Bril, Hans-Peter Hartung, John-Philip Lawo, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|September 22, 2007
Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthmaHelgo Magnussen, Jerzy Hofman, Pawel Staneta, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 13, 2011
A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassaysThomas Jaki, John-Philip Lawo, Martin J Wolfsegger, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|July 22, 2021
Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathyMonica Alcantara, Hans-Peter Hartung, John-Philip Lawo, et al.
Transfusion|May 16, 2020
Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reportsAmgad Shebl, Susie Gabriel, Kristy Van Dinther, et al.
Clinical Immunology (Orlando, Fla.)|January 14, 2014
Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency diseaseStephen Jolles, Michael Borte, Robert P Nelson, et al.
Journal of Clinical Pharmacology|November 25, 2024
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous and Intravenous Garadacimab Following Single-Dose Administration in Healthy Japanese and White AdultsFiona Glassman, John-Philip Lawo, Mihai Alexandru Bica, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Journal of Clinical Immunology|February 25, 2016
Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary ImmunodeficiencyMikhail A Rojavin, Alphonse Hubsch, John-Philip Lawo
Journal of Biopharmaceutical Statistics|May 25, 2010
Establishing bioequivalence in complete and incomplete data designs using AUCsThomas Jaki, Martin J Wolfsegger, John-Philip Lawo
Journal of Pharmaceutical and Biomedical Analysis|September 10, 2013
A comparison of methods for classifying samples as truly specific with confirmatory immunoassaysThomas Jaki, John-Philip Lawo, Martin J Wolfsegger, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|October 11, 2020
Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) studyVera Bril, Hans-Peter Hartung, John-Philip Lawo, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|September 22, 2007
Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthmaHelgo Magnussen, Jerzy Hofman, Pawel Staneta, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 13, 2011
A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassaysThomas Jaki, John-Philip Lawo, Martin J Wolfsegger, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|July 22, 2021
Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathyMonica Alcantara, Hans-Peter Hartung, John-Philip Lawo, et al.
Transfusion|May 16, 2020
Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reportsAmgad Shebl, Susie Gabriel, Kristy Van Dinther, et al.
Clinical Immunology (Orlando, Fla.)|January 14, 2014
Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency diseaseStephen Jolles, Michael Borte, Robert P Nelson, et al.
Journal of Clinical Pharmacology|November 25, 2024
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous and Intravenous Garadacimab Following Single-Dose Administration in Healthy Japanese and White AdultsFiona Glassman, John-Philip Lawo, Mihai Alexandru Bica, et al.
Pageof 4